"CHP waters joint open laboratory" unveils the introduction of advanced technology into the composition analysis of traditional Chinese Medicine

"CHP waters joint open laboratory" is located in the experimental building of Beijing Zhendong Guangming Pharmaceutical Research Institute, covering an area of about 400 square meters It is understood that as a public welfare project, the experiment will carry out in-depth research on Pharmacopoeia standards, detection methods, development and validation At the same time, it will also carry out the analysis methods and data comparison of Pharmacopoeia standards at home and abroad, provide training for drug regulatory and drug production researchers, carry out international technical exchanges for drug research and development, and become a technical support center, innovation center and exchange and cooperation center with international vision and level As a company engaged in separation science, laboratory information management, mass spectrometry and thermal analysis technology, waters actively participates in Pharmacopoeia research work of Pharmacopoeia committees around the world, and provides technical support and services in the construction of Pharmacopoeia laboratories in various countries Photo annotation: representatives from Watson, China Pharmacopoeia Committee, Chinese Academy of engineering, Chinese Academy of Sciences, Zhendong group, etc jointly opened the laboratory (from left to right: academician Liu Changxiao, academician Yao Xinsheng, Mr Mike Harrington, academician Zhang Boli, chairman Zhang Weimi, academician Chen Kaixian, and Mr Li Anping) Photo note: Mike Harrington, vice president of Asia Pacific and European operations of Watson company, and Zhang Wei, Secretary General of China Pharmacopoeia Committee jointly opened the laboratory The reporter learned that as a public welfare project, the joint open laboratory has been widely concerned by the industry since it was announced According to Zhang Wei, the laboratory is built by gathering various social resources, aiming to fully fulfill its mission of openness, public welfare, innovation and mutual benefit, and better serve and contribute to the research of Chinese Pharmacopoeia "In the future development and operation of the laboratory, we should still adhere to the public welfare and the purpose of serving the society We hope that more enterprises and social forces can join in this public welfare." Zhang Wei stressed It is reported that "CHP waters joint open laboratory" is located in the experimental building of Beijing Zhendong Guangming Pharmaceutical Research Institute, covering an area of more than 400 square meters On the one hand, we will carry out in-depth research on Pharmacopoeia standards, detection methods, development and verification; on the other hand, we will carry out the analytical methods of Pharmacopoeia standards at home and abroad, and the data comparison of various theories The laboratory will also provide training for drug regulatory and production researchers, and conduct extensive international technical exchanges on drug development and research In view of the openness of the laboratory, each unit undertaking the task of Pharmacopoeia research may, according to the needs, apply for the person or bring the subject to the laboratory for experimental research using advanced and new-type instruments and equipment The two sides hope that the laboratory will eventually become a national level technical support center in the field of Chinese drug standards It is reported that as a partner, Watson has very extensive cooperation with Pharmacopoeia Committee members all over the world Mike Harrington, vice president of Asia Pacific and European operations of Watson company, told reporters: "take the cooperation with USPC as an example, the cooperation between waters and USP, including the development and joint training of some methods, the change and revision of the contents of the Pharmacopoeia, and also provide some consulting services to the USPC, especially the methods like using ultra high performance liquid chromatography (UPLC)." Mike Harrington says the challenges facing the pharmaceutical industry in different countries are different "Take the Pharmacopoeia of China and the United States for example, most of the compounds contained in the United States are very simple small molecular compounds, but the Pharmacopoeia of China includes many traditional drugs and traditional Chinese medicines, and the composition of these compounds is much more complex So, relatively speaking, analysis and detection are much more difficult " Mike Harrington said: "but it is precisely because of this that Watson sees the opportunity to cooperate with the Chinese Pharmacopoeia Watson can help the Chinese Pharmacopoeia to carry out in-depth cooperation on such aspects as analysis, verification and identification of traditional Chinese medicine " The reporter learned that in 2015, the new edition of Chinese Pharmacopoeia will be officially published Zhang Liangyu, President of Watson Greater China, told reporters that Watson will play two roles in the revision of the new pharmacopoeia "One is the classification of drug varieties and the revision of the new catalogue, and Watson will provide more efficient advice; the other is the introduction of new technologies "Watson will introduce UPLC technology and upc2 (ultra high performance chromatography) technology into the analysis of traditional Chinese medicine, which will provide more accurate analysis results than the previous LC (liquid chromatography) technology." About Watson (www.waters Com) for more than 50 years, Watson (NYSE: WAT) has made significant progress in the fields of medical services, environmental management, food safety and global water quality monitoring by providing practical and sustainable innovation, thus creating business advantages for laboratory related institutions As the pioneer of a series of separation science, laboratory information management, mass spectrometry and thermal analysis technology, the major breakthrough and laboratory solutions of Watson technology create a lasting platform for the success of customers With $1.9 billion in revenue in 2013, Watson will continue to lead customers around the world to explore analytical science and achieve outstanding results The State Pharmacopoeia Committee introduced that the State Pharmacopoeia Committee (formerly known as the Pharmacopoeia Committee of the Ministry of Health) was established in 1950 According to the provisions of the drug administration law of the people's Republic of China, it is responsible for organizing the compilation of the Pharmacopoeia of the people's Republic of China and the formulation and revision of the national drug standards It is a statutory professional management organization for the work of national drug standards The permanent office of the pharmacopoeia committee adopts the secretary general responsibility system, which consists of offices, human resources department, comprehensive business department, drug information department, traditional Chinese medicine department, chemical medicine department, biological products department, as well as branches such as China drug standard magazine The permanent office of the national pharmacopoeia committee has a staff of 50, with the existing staff (including the employed staff and the following staff) About 90 people.